BioScrip Inc. (BIOS) Position Boosted by California Public Employees Retirement System
California Public Employees Retirement System increased its position in shares of BioScrip Inc. (NASDAQ:BIOS) by 14.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 464,100 shares of the company’s stock after buying an additional 60,300 shares during the period. California Public Employees Retirement System owned approximately 0.67% of BioScrip worth $1,184,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Emerald Acquisition Ltd. acquired a new stake in BioScrip during the second quarter worth about $318,000. Roanoke Asset Management Corp NY boosted its stake in BioScrip by 68.2% in the second quarter. Roanoke Asset Management Corp NY now owns 277,020 shares of the company’s stock worth $706,000 after buying an additional 112,325 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in BioScrip by 10.7% in the second quarter. Bank of New York Mellon Corp now owns 301,166 shares of the company’s stock worth $768,000 after buying an additional 28,993 shares during the last quarter. Keane Capital Partners LLC acquired a new stake in BioScrip during the first quarter worth about $880,000. Finally, Geode Capital Management LLC boosted its stake in BioScrip by 1.2% in the first quarter. Geode Capital Management LLC now owns 452,925 shares of the company’s stock worth $969,000 after buying an additional 5,437 shares during the last quarter. 82.89% of the stock is owned by institutional investors.
BioScrip Inc. (NASDAQ:BIOS) traded down 1.29% during mid-day trading on Friday, reaching $3.05. The company had a trading volume of 394,757 shares. The firm’s market capitalization is $347.33 million. BioScrip Inc. has a one year low of $1.19 and a one year high of $3.43. The firm’s 50-day moving average is $2.86 and its 200-day moving average is $2.65.
BioScrip (NASDAQ:BIOS) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.05. The firm earned $232.50 million during the quarter, compared to analysts’ expectations of $229.58 million. The company’s revenue for the quarter was down 11.4% compared to the same quarter last year. On average, equities research analysts anticipate that BioScrip Inc. will post ($0.27) earnings per share for the current fiscal year.
Separately, Zacks Investment Research raised BioScrip from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Monday, July 11th.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip Inc. (NASDAQ:BIOS).
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.